C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival

Cell Signal. 2009 Jul;21(7):1229-35. doi: 10.1016/j.cellsig.2009.03.015. Epub 2009 Mar 24.

Abstract

In this work we report evidences of a functional relationship between C3G and p38 MAPK in the apoptotic effect of STI-571 on the chronic myeloid leukemia (CML) cell line K562. This has been demonstrated by knocking down C3G and p38alpha using the interfering RNA approach, as well as through targeting p38 by its inhibitor SB203580. The results indicate that p38 is a mediator of the STI-571-induced apoptosis, while C3G plays a negative role on STI-571-mediated p38 activation through a Rap1-dependent mechanism. According to this, gene expression analysis in C3G silenced cells revealed an upregulation of a large number of genes involved in apoptosis. Some of these genes are also down-regulated (at the protein level) upon p38alpha knock-down, which further suggests a functional association between these two proteins. On the other hand, C3G knock-down reverts the STI-571-inhibitory effect on ERKs and Akt pathways in a Rap1-independent fashion. Moreover, C3G overexpression also increased both, basal and STI-571-induced apoptosis, in agreement with previous reports. Therefore, our results strongly suggest a dual regulatory role for C3G in CML cells, modulating both apoptosis and survival via Rap-dependent and independent mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects*
  • Benzamides
  • Cell Survival / drug effects
  • Enzyme Activation / drug effects
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Silencing / drug effects*
  • Guanine Nucleotide-Releasing Factor 2 / genetics*
  • Humans
  • Imatinib Mesylate
  • Immunoblotting
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Models, Biological
  • Piperazines / pharmacology*
  • Pyrimidines / pharmacology*
  • Signal Transduction / drug effects
  • Transcription, Genetic / drug effects
  • p38 Mitogen-Activated Protein Kinases / metabolism*
  • rap1 GTP-Binding Proteins / metabolism

Substances

  • Antineoplastic Agents
  • Benzamides
  • Guanine Nucleotide-Releasing Factor 2
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • p38 Mitogen-Activated Protein Kinases
  • rap1 GTP-Binding Proteins